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system the combined screening/risk-based strategy and
the risk-based strategy are efﬁcient strategies with rea-
sonable cost-effectiveness.
PIN34
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STRATEGIES FOR CHLAMYDIA TRACHOMATIS
INFECTIONS IN FRANCE
Préaubert N, Delaveyne R
ANAES, Saint Denis la Plaine Cedex, France
OBJECTIVES: To evaluate two screening programs for
Chlamydia Trachomatis (CT) in France by measuring cost
per case and cost per treated case. METHODS: We eval-
uated the cost-effectiveness ratios of two CT screening
strategies using a decision tree model. Strategy A involved
screening of asymptomatic women only with partner
notiﬁcation; Strategy B involved screening of both asymp-
tomatic men and women with partner notiﬁcation. The
current strategy of no screening was not evaluated. Clin-
ical pathways were validated by a panel of experts. Direct
cost analysis was performed from the point of view of the
French National Health Insurance System. RESULTS:
Overall, 347 women, and their partners could be treated
by strategy A, and 296 individuals and their partners by
strategy B. The total cost of strategy B was lower than
that of strategy A (€213,400 compared to €250,558).
Costs per case and costs per treated case were compara-
ble for the two strategies, €557 and €722 respectively.
According to a sensitivity analysis, the key variables were:
CT prevalence, male participation rate, and likelihood
that a man should consult a doctor. CONCLUSIONS:
This is the ﬁrst model for CT screening built on French
data and thus a useful tool for French health policy deci-
sion-makers as it provides estimates for budgetary impact
analysis. Its limitations are the hypotheses on which it is
based (averted outcomes, direct costs . . .). Besides com-
paring the cost-effectiveness of screening, our study high-
lighted the need to standardize clinical practice and
develop a good communication program.
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OBJECTIVES: To estimate the incremental cost-
effectiveness ratio (ICER) of routine meningococcal
serogroup C conjugate vaccination of children at 2, 3,
and 4, or at 5 and 6 months instead of at 14 months in
the Netherlands and to determine the impact of includ-
ing herd-immunity. METHODS: The analysis was per-
formed from a societal perspective and in accordance to
the Dutch guidelines for pharmacoeconomic research,
using a cohort model. Direct and indirect (friction cost
method) costs were considered. Future costs and effects
were discounted at 4% and 2000 was chosen as baseline
year. A vaccine effectiveness of 90% (based on UK data)
and a vaccine protection duration of 20 years (based on
the experience with Haemophilus inﬂuenzae type b) were
used. Also on the basis of UK data, we assumed that 70%
of all unvaccinated persons aged 0–14 months are pro-
tected because of the herd-immunity effect caused by 
the recent meningococcal C conjugate vaccination of all
persons aged 14 months to 18 years. RESULTS: For
immunization of children at 2, 3, and 4 (5 + 6) months,
the herd-immunity effect decreases the yearly number of
additional life years gained from 51 (36) to 15 (11) but
leads to a strong increase of the ICER from €149,000
(€105,000) per life year gained to €497,000 (€349,000)
per life year gained. Even if only a herd-immunity effect
of 50% is assumed, the ICER still increases to about
€298,000 (€209,000) per life year gained. These results
are sensitive to the protection duration and effectiveness
of the vaccine and the meningococcal C incidence. CON-
CLUSIONS: The inclusion of herd-immunity decreases
the rendered small health gain and thus leads to even less
favorable cost-effectiveness ratios for vaccination of chil-
dren aged less than one year. Hence, the current Dutch
vaccination strategy of routine vaccinating children at 14
months should not be changed.
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Respiratory syncytial virus (RSV) is a leading cause of a
lower respiratory tract infection in infants and is respon-
sible for increased hospitalization, morbidity, and deaths
amongst high-risk individuals including those who are
born prematurely. As the treatment of RSV infections is
limited the analysis was focused on prophylactic therapy
with palivizumab, a humanized murine monoclonal anti-
body that provides passive immunity against RSV.
OBJECTIVES: To evaluate costs and cost-effectiveness of
RSV prophylaxis among infants born at less than 32
weeks gestation in Poland. METHODS: Decision tree
analysis was used to compare cost-effectiveness of two
strategies, palivizumab and no prophylaxis, among a
hypothetical cohort of infants born <32 gestational age.
Probabilities were derived from published trials. Costs
encompassed: drug costs, costs of non-intensive and
intensive pediatric hospital care and costs of asthma treat-
ment up to age 7. The discount rate of costs was set at
759Abstracts
3%. The cost-effectiveness ratio was expressed as cost of
life year gained with RSV prophylaxis. Sensitivity analy-
ses were performed for the key probabilities. RESULTS:
Palivizumab prophylaxis was estimated to cost €8903 per
life gained as compared to €6594 for no preventive treat-
ment. The incremental cost-effectiveness ratio of one life
year gained amounted to €13,246 (PPP: €1 = 1.9 PLN).
The sensitivity analysis indicated that the results were sen-
sitive to the probability of hospitalization for RSV for 
no prophylaxis. CONCLUSIONS: Palivizumab, as com-
pared to other widely accepted medical procedures,
appeared to be cost-effective prophylaxis for the preven-
tion of serious lower respiratory-tract infection caused by
RSV in infants born at less than 32 weeks gestation in
Poland.
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OBJECTIVES: The objective is to discuss and evaluate
potential changes in patient, physician, and organisa-
tional behavior related to the introduction of a new health
care technology (treatment of inﬂuenza with the anti-viral
neuraminidase inhibitors). The changes evaluated are: 1)
increased health care seeking by patients, due to the avail-
ability of antivirals for inﬂuenza; 2) Crowding out of
inappropriate anti-biotic prescribing for inﬂuenza by
antivirals; and 3) System change to allow telephone nurse
prescribing rather than GP consultation. METHODS:
Some unique characteristics of neuramindase inhibitors
has important implications for their cost-effectiveness 
in any given health care systems. A health economic 
decision model is employed in order to evaluate some of
these potential changes when introducing treatment of
inﬂuenza with neuraminidase inhibitors. The impact on
cost-effectiveness and cost-utility of three different behav-
ioural changes are investigated with the model as well as
the base line cost-effectiveness and cost-utility of treating
healthy adults in UK. RESULTS: The results of the eco-
nomic modeling show that treatment of inﬂuenza in
healthy adults with the anti-viral oseltamivir has incre-
mental cost-utility ratios between £4,775/QALY (base-
line) and £15,772/QALY (increased health care seeking
by patients). CONCLUSION: In order to make a deci-
sion regarding introduction of inﬂuenza treatment with
the new technology a number of issues ought to be
addressed. These may be best dealt with in a full HTA
where all aspects of introducing a new technology are
investigated. By only evaluating certain aspects of the
introduction of the technology, decision makers are likely
to make decisions based on incomplete information. This
may result in sub-optimal patient treatment and resource
use in society.
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OBJETIVE: The hepatitis C treatment with conven-
tional interferon monotherapy has been under discussion
because of its low response rate (10–20%). However,
combination therapies involving ribavirin and the new
two pegylated interferons have raised the response rates
beyond 50%. This study analyses the cost-effectiveness
ratios for two different peginterferons (peginterferon alfa-
2a and peginterferon alfa-2b) plus ribavirin compared
with interferon-alfa 2b plus ribavirin. METHOD: A
Markov model was developed to represent the natural
history of hepatitis C and to estimate the incremental
cost-effectiveness ratios for the two different peginterfer-
ons plus ribavirin compared with interferon-alfa 2b plus
ribavirin. The results of two indipendent clinical trials
comparing these treatment alternatives in naive patients
with HCV infection and no co-morbidity have been
obtained from several publications. The model was
applied separately to both trials. To evaluate the natural
history of decompensated cirrhosis, 200 patients with
decompensated liver disease from hepatitis C etiology
were studied depending on the ﬁrst decompensation event
in two different hospitals in Spain. RESULTS: The results
indicate costs of €20,751/life-year gained using efﬁcacy
data from the peginterferon alfa-2b trial and €10,350/life-
year gained employing the peginterferon alfa-2a trial
data. When a test is used at 12 weeks to facilitate an early
detection of non-responders, the ﬁgures lower to €14,037
and €6,605/life-year gained, respectively. CONCLU-
SION: The main conclusion is that the combined treat-
ment of peginterferon plus ribavirin is cost-effective
showing peginterferon alfa-2a a better cost-effectiveness
ratio than peginterferon alfa-2b. Efﬁciency decreases with
advancing age and can be increased when strategies of
early selection are employed to identify those patients
who, without sustained viral response, would not beneﬁt
from the treatment.
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